RU2013157877A - Модуляторы атф-связывающих кассетных транспортеров - Google Patents
Модуляторы атф-связывающих кассетных транспортеров Download PDFInfo
- Publication number
- RU2013157877A RU2013157877A RU2013157877/04A RU2013157877A RU2013157877A RU 2013157877 A RU2013157877 A RU 2013157877A RU 2013157877/04 A RU2013157877/04 A RU 2013157877/04A RU 2013157877 A RU2013157877 A RU 2013157877A RU 2013157877 A RU2013157877 A RU 2013157877A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- disease
- composition
- hereditary
- agent
- Prior art date
Links
- MJUVRTYWUMPBTR-INIZCTEOSA-N CC(C)(CO)c([n](C[C@@H](CO)O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F Chemical compound CC(C)(CO)c([n](C[C@@H](CO)O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F MJUVRTYWUMPBTR-INIZCTEOSA-N 0.000 description 1
- MJUVRTYWUMPBTR-MRXNPFEDSA-N CC(C)(CO)c([n](C[C@H](CO)O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F Chemical compound CC(C)(CO)c([n](C[C@H](CO)O)c1c2)cc1cc(NC(C1(CC1)c(cc1)cc(O3)c1OC3(F)F)=O)c2F MJUVRTYWUMPBTR-MRXNPFEDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1. Соединение, выбранное из2. Соединение3. Соединение4. Соединение5. Фармацевтическая композиция, содержащая(i) соединение по п. 1 и(ii) фармацевтически приемлемый носитель.6. Композиция по п. 5, дополнительно содержащая дополнительное средство, выбранное из муколитического средства, бронхолитического средства, антибиотика, антибактериального средства, противовоспалительного средства, корректора CFTR, усилителя CFTR или питательного средства.7. Композиция по п. 5 или 6, в которой соединение представляет собой8. Композиция по п. 5 или 6, в которой соединение представляет собой9. Композиция по п. 5 или 6, в которой соединение представляет собой10. Способ повышения количества функцинальных ABC-транспортеров в мембране клетки, включающий стадию контактирования указанной клетки с соединением, выбранным из11. Способ по п. 10, в котором ABC-транспортер представляет собой CFTR.12. Способ по п. 10 или 11, в котором соединение представляет собой13. Способ по п. 10 или 11, в котором соединение представляет собой14. Способ по п. 10 или 11, в котором соединение представляет собой15. Способ лечения состояния, заболевания или расстройства у пациента, в патологии которого задействована активность ABC-транспортера, включающий стадию введения указанному пациенту соединения, выбранного из16. Способ по п. 15, в котором указанное состояние, заболевание или расстройство выбрано из муковисцидоза, наследственной эмфиземы, наследственного гемохроматоза,недостаточностей факторов свертывания крови и фибринстабилизирующего фактора, таких как дефицит белка С, наследственный ангионеврологический отек 1 типа, дефектов в процессинге липидов, таких как семейная гиперхолестер
Claims (25)
5. Фармацевтическая композиция, содержащая
(i) соединение по п. 1 и
(ii) фармацевтически приемлемый носитель.
6. Композиция по п. 5, дополнительно содержащая дополнительное средство, выбранное из муколитического средства, бронхолитического средства, антибиотика, антибактериального средства, противовоспалительного средства, корректора CFTR, усилителя CFTR или питательного средства.
11. Способ по п. 10, в котором ABC-транспортер представляет собой CFTR.
16. Способ по п. 15, в котором указанное состояние, заболевание или расстройство выбрано из муковисцидоза, наследственной эмфиземы, наследственного гемохроматоза,
недостаточностей факторов свертывания крови и фибринстабилизирующего фактора, таких как дефицит белка С, наследственный ангионеврологический отек 1 типа, дефектов в процессинге липидов, таких как семейная гиперхолестеринемия, хиломикронемия 1 типа, абеталипопротеинемия, лизосомных болезней, таких как болезнь клеточных включений/псевдо-Хюрлера, мукополисахаридозы, болезнь Сандхоффа/Тея-Сакса, болезнь Криглера-Найяра II типа, полиэндокринопатия/гиперинсулинемия, сахарный диабет, карликовость Ларона, дефицит милеопероксидазы, первичный гипопаратиреоидизм, меланома, гликогеноз CDG 1 типа, наследственная эмфизема, врожденный гипертиреоидизм, несовершенный остеогенез, наследственная гипофибриногенемия, недостаточность ACT, несахарный диабет (di), нейрофизиологический di, нефрогенный DI, синдром Шарко-Мари-Тута, болезнь Пелицеуса-Мерцбахера, нейродегенеративных заболеваний, таких как болезнь Альцгеймера, болезнь Паркинсона, боковой амиотрофический склероз, прогрессирующий супрануклеарный паралич, болезнь Пика, некоторых неврологических расстройств, связанных с обменом глутамина, таких как болезнь Гентингтона, спинномозговая атаксия I типа, спинально-бульбарная мышечная атрофия, дентаторубральная и паллидолюисовая атрофия и миотоническая дистрофия, а также губчатых энцефалопатий, таких как наследственная болезнь Крейтцфельдта-Якоба, болезнь Фабри, синдром Штраусслера-Шейнкера, хроническое обструктивное заболевание легких (COPD), болезнь сухих глаз и синдром Шегрена.
20. Набор для измерения активности ABC-транспортера или его фрагмента в биологическом образце in vitro или in vivo, содержащий
(i) первую композицию, содержащую соединение, выбранное из соединения по п. 1; и
(ii) инструкции для
а) контактирования композиции с биологическим образцом;
b) измерения активности указанного ABC-транспортера или его
фрагмента.
21. Набор по п. 20, дополнительно содержащий инструкции для
а) контактирования дополнительной композиции с биологическим образцом;
b) измерения активности указанного ABC-транспортера или его фрагмента в присутствии указанного дополнительного соединения и
c) сравнения активности ABC-транспортера в присутствии дополнительного соединения с плотностью ABC-транспортера в присутствии указанной первой композиции.
22. Набор по п. 20, предназначенный для измерения плотности CFTR.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11215208P | 2008-11-06 | 2008-11-06 | |
US11214508P | 2008-11-06 | 2008-11-06 | |
US61/112,145 | 2008-11-06 | ||
US61/112,152 | 2008-11-06 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011122461A Division RU2512682C3 (ru) | 2008-11-12 | Модуляторы атф-связывающих кассетных транспортеров |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013157877A true RU2013157877A (ru) | 2015-06-27 |
Family
ID=40933810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013157877/04A RU2013157877A (ru) | 2008-11-06 | 2013-12-25 | Модуляторы атф-связывающих кассетных транспортеров |
Country Status (31)
Country | Link |
---|---|
EP (2) | EP2940016A1 (ru) |
JP (4) | JP5600322B2 (ru) |
KR (3) | KR101587389B1 (ru) |
CN (2) | CN102272127A (ru) |
AU (1) | AU2008363828B2 (ru) |
BR (1) | BRPI0823228B8 (ru) |
CA (1) | CA2742821C (ru) |
CL (1) | CL2011001027A1 (ru) |
CY (2) | CY1116067T1 (ru) |
DK (1) | DK2365972T3 (ru) |
ES (1) | ES2532753T3 (ru) |
FR (1) | FR19C1017I2 (ru) |
HK (2) | HK1162477A1 (ru) |
HR (1) | HRP20150288T1 (ru) |
HU (1) | HUS1900015I1 (ru) |
IL (3) | IL212737A (ru) |
LT (1) | LTC2365972I2 (ru) |
LU (1) | LUC00110I2 (ru) |
ME (1) | ME02105B (ru) |
MX (2) | MX357497B (ru) |
NL (1) | NL300984I9 (ru) |
NO (1) | NO2019015I1 (ru) |
NZ (2) | NZ609962A (ru) |
PL (1) | PL2365972T3 (ru) |
PT (1) | PT2365972E (ru) |
RS (1) | RS53868B1 (ru) |
RU (1) | RU2013157877A (ru) |
SI (1) | SI2365972T1 (ru) |
UA (1) | UA121188C2 (ru) |
WO (1) | WO2010053471A1 (ru) |
ZA (1) | ZA201103883B (ru) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
HUE032640T2 (en) | 2005-11-08 | 2017-10-30 | Vertex Pharma | Heterocyclic modulator of ATP-binding cassette transcripts |
LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
DK3091011T3 (en) | 2006-04-07 | 2018-02-26 | Vertex Pharma | MODULATORS OF ATP BINDING CASSETTE TRANSPORT |
US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
US8969386B2 (en) | 2007-05-09 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
KR20100101130A (ko) | 2007-12-07 | 2010-09-16 | 버텍스 파마슈티칼스 인코포레이티드 | 3-(6-(1-(2,2-디플루오로벤조[d][1,3]디옥솔-5-일)사이클로프로판카복스아미도)-3-메틸피리딘-2-일)벤조산의 고체 형태 |
CA2707494C (en) | 2007-12-07 | 2018-04-24 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
DK2365972T3 (en) * | 2008-11-06 | 2015-01-19 | Vertex Pharma | Modulators of atp-binding cassette conveyors |
UA104876C2 (ru) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модуляторы атф-связывающих кассетных транспортеров |
EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
PL3835297T3 (pl) * | 2010-03-25 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Synteza i związki pośrednie (r)-1-(2,2-difluorobenzo[d][1,3]-dioksol-5-ilo)-n-(1-(2,3-dihydroksypropylo)-6-fluoro-2-(1-hydroksy-2-metylopropan-2-ylo)-1h-indol-5-ilo)-cyklopropanokarboksyamidu |
LT3150198T (lt) | 2010-04-07 | 2021-12-10 | Vertex Pharmaceuticals Incorporated | 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties farmacinė kompozicija ir jos įvedimas |
SG184987A1 (en) | 2010-04-22 | 2012-11-29 | Vertex Pharma | Process of producing cycloalkylcarboxamido-indole compounds |
EP2560649A1 (en) * | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
WO2011133953A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CA2796646A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
CN103153287A (zh) * | 2010-08-23 | 2013-06-12 | 弗特克斯药品有限公司 | (R)-1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-N-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用 |
WO2013070961A1 (en) * | 2011-11-08 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
WO2013130669A1 (en) | 2012-02-27 | 2013-09-06 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
BR112015023328A2 (pt) | 2013-03-13 | 2017-07-18 | Flatley Discovery Lab | compostos de piridazinona e métodos para o tratamento de fibrose cística |
WO2014141064A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
PT3068392T (pt) | 2013-11-12 | 2021-05-14 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por condutância transmembrana da fibrose quística (cftr) |
PL3925607T3 (pl) | 2014-04-15 | 2023-10-30 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
HUE048020T2 (hu) | 2014-05-12 | 2020-05-28 | Verona Pharma Plc | Új kezelés |
CN112250627B (zh) | 2014-10-06 | 2024-02-02 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
AU2015330923B2 (en) | 2014-10-07 | 2020-03-12 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
HUE055423T2 (hu) | 2014-11-18 | 2021-11-29 | Vertex Pharma | Eljárás nagy áteresztõképességû tesztelõ nagy teljesítményû folyadék-kromatográfia elvégzésére |
EA201791500A1 (ru) | 2014-12-31 | 2018-01-31 | Оспекс Фармасьютикалз, Инк. | Циклопропанкарбоксамидные модуляторы муковисцидозного трансмембранного регулятора проводимости |
GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
US10196384B2 (en) | 2015-03-31 | 2019-02-05 | Vertex Pharmaceuticals (Europe) Limited | Deuterated CFTR modulators |
CN105153106B (zh) * | 2015-09-02 | 2017-08-25 | 阜新奥瑞凯新材料有限公司 | 一种2,2‑二氟胡椒酸甲酯的制备方法 |
GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
US10047077B2 (en) | 2016-04-13 | 2018-08-14 | Skyline Antiinfectives, Inc. | Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams |
JP6601365B2 (ja) | 2016-07-27 | 2019-11-06 | 株式会社デンソー | 制御システム |
EP3519401B1 (en) | 2016-09-30 | 2021-09-29 | Vertex Pharmaceuticals Incorporated | Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
IL277491B (en) * | 2016-12-09 | 2022-08-01 | Vertex Pharma | Modulatory modulation of transmembrane conductance in cystic fibrosis, pharmaceutical preparations, treatment methods, and a process for creating the modulator |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
CN111051280B (zh) | 2017-08-02 | 2023-12-22 | 弗特克斯药品有限公司 | 制备吡咯烷化合物的方法 |
US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
US10654829B2 (en) | 2017-10-19 | 2020-05-19 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
MD3752510T2 (ro) | 2018-02-15 | 2023-06-30 | Vertex Pharma | Macrociclii ca modulatori ai regulatorului conductanței transmembranare în fibroza chistică, compoziții farmaceutice ale acestora, utilizarea lor în tratamentul fibrozei chistice, și procedeu pentru fabricarea acestora |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
CN111763198B (zh) * | 2019-04-01 | 2021-09-07 | 新发药业有限公司 | 一种5-取代环丙基甲酰氨基吲哚衍生物的制备方法 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
AU2020328568A1 (en) | 2019-08-14 | 2022-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
EP4099991A1 (en) * | 2020-02-05 | 2022-12-14 | Laurus Labs Limited | Novel processes for preparation of tezacaftor |
CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
US20230303589A1 (en) | 2020-08-13 | 2023-09-28 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
WO2022076620A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
PE20231108A1 (es) | 2020-10-07 | 2023-07-19 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica |
WO2022076629A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225737A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
AU2021358063A1 (en) | 2020-10-07 | 2023-05-18 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
EP4225763A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2022076618A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
BR112023006470A2 (pt) | 2020-10-07 | 2023-09-26 | Vertex Pharma | Moduladores de regulador de condutância transmembrana de fibrose cística |
WO2022076621A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
CA3204725A1 (en) | 2020-12-10 | 2022-06-16 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
DK3091011T3 (en) | 2006-04-07 | 2018-02-26 | Vertex Pharma | MODULATORS OF ATP BINDING CASSETTE TRANSPORT |
DK2365972T3 (en) * | 2008-11-06 | 2015-01-19 | Vertex Pharma | Modulators of atp-binding cassette conveyors |
UA104876C2 (ru) * | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модуляторы атф-связывающих кассетных транспортеров |
-
2008
- 2008-11-12 DK DK08876364.4T patent/DK2365972T3/en active
- 2008-11-12 JP JP2011535544A patent/JP5600322B2/ja active Active
- 2008-11-12 CN CN2008801326311A patent/CN102272127A/zh active Pending
- 2008-11-12 KR KR1020157006518A patent/KR101587389B1/ko active Application Filing
- 2008-11-12 SI SI200831394T patent/SI2365972T1/sl unknown
- 2008-11-12 NZ NZ609962A patent/NZ609962A/en unknown
- 2008-11-12 ES ES08876364.4T patent/ES2532753T3/es active Active
- 2008-11-12 UA UAA201312737A patent/UA121188C2/uk unknown
- 2008-11-12 EP EP14197820.5A patent/EP2940016A1/en not_active Withdrawn
- 2008-11-12 NZ NZ592694A patent/NZ592694A/xx not_active IP Right Cessation
- 2008-11-12 KR KR1020117012764A patent/KR101559963B1/ko active IP Right Grant
- 2008-11-12 ME MEP-2015-37A patent/ME02105B/me unknown
- 2008-11-12 RS RS20150170A patent/RS53868B1/en unknown
- 2008-11-12 MX MX2013012665A patent/MX357497B/es unknown
- 2008-11-12 AU AU2008363828A patent/AU2008363828B2/en active Active
- 2008-11-12 CA CA2742821A patent/CA2742821C/en active Active
- 2008-11-12 MX MX2011004832A patent/MX2011004832A/es active IP Right Grant
- 2008-11-12 BR BRPI0823228A patent/BRPI0823228B8/pt active IP Right Grant
- 2008-11-12 PL PL08876364T patent/PL2365972T3/pl unknown
- 2008-11-12 KR KR1020167000956A patent/KR20160013251A/ko not_active Application Discontinuation
- 2008-11-12 CN CN201711204617.5A patent/CN108117546A/zh active Pending
- 2008-11-12 WO PCT/US2008/012689 patent/WO2010053471A1/en active Application Filing
- 2008-11-12 PT PT08876364T patent/PT2365972E/pt unknown
- 2008-11-12 EP EP08876364.4A patent/EP2365972B1/en active Active
-
2011
- 2011-05-05 IL IL212737A patent/IL212737A/en active Pre-grant Review Request
- 2011-05-09 CL CL2011001027A patent/CL2011001027A1/es unknown
- 2011-05-26 ZA ZA2011/03883A patent/ZA201103883B/en unknown
-
2012
- 2012-03-16 HK HK12102660.1A patent/HK1162477A1/xx unknown
-
2013
- 2013-12-25 RU RU2013157877/04A patent/RU2013157877A/ru not_active Application Discontinuation
-
2014
- 2014-07-28 IL IL233837A patent/IL233837A/en active IP Right Grant
- 2014-08-15 JP JP2014165547A patent/JP5728611B2/ja active Active
-
2015
- 2015-03-03 CY CY20151100222T patent/CY1116067T1/el unknown
- 2015-03-16 HR HRP20150288TT patent/HRP20150288T1/hr unknown
- 2015-04-06 JP JP2015077925A patent/JP5905620B2/ja active Active
- 2015-06-30 IL IL239713A patent/IL239713A/en active Protection Beyond IP Right Term
-
2016
- 2016-03-16 JP JP2016052743A patent/JP2016147887A/ja active Pending
- 2016-04-15 HK HK16104342.9A patent/HK1216526A1/zh unknown
-
2019
- 2019-03-13 HU HUS1900015C patent/HUS1900015I1/hu unknown
- 2019-03-15 FR FR19C1017C patent/FR19C1017I2/fr active Active
- 2019-03-21 LT LTPA2019505 patent/LTC2365972I2/lt unknown
- 2019-03-21 LU LU00110C patent/LUC00110I2/fr unknown
- 2019-04-04 NO NO2019015C patent/NO2019015I1/no unknown
- 2019-04-29 NL NL300984C patent/NL300984I9/nl unknown
- 2019-04-30 CY CY2019023C patent/CY2019023I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013157877A (ru) | Модуляторы атф-связывающих кассетных транспортеров | |
RU2011122646A (ru) | Модуляторы переносчиков атф-связывающих кассет | |
RU2011142297A (ru) | Модуляторы регулятора трансмембранной проводимости кистозного фиброза | |
De Oliveira et al. | The mechanism of sirtuin 2–mediated exacerbation of alpha-synuclein toxicity in models of Parkinson disease | |
JP2011505338A5 (ru) | ||
HRP20170458T1 (hr) | Modulatori atp - vezujućih kasetnih transportera | |
RU2008122929A (ru) | Гетероциклические модуляторы транспортеров атф-связывающей кассеты | |
JP2012521361A5 (ru) | ||
RU2008118001A (ru) | Модуляторы атф-зависимых транспортеров | |
HRP20180328T1 (hr) | FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE | |
JP2011513321A5 (ru) | ||
RU2012121168A (ru) | Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида | |
IL273752B1 (en) | Ingredients, compounds and methods for increasing cftr activity | |
JP2009521468A5 (ru) | ||
SI3091011T1 (en) | Modulators of ATP conveyor belt conveyors | |
JP2009514962A5 (ru) | ||
RU2014139006A (ru) | Фармацевтическая композиция и ее введения | |
JP2013501787A5 (ru) | ||
JP2007519740A5 (ru) | ||
Rapino et al. | Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation | |
JP2010526831A5 (ru) | ||
Gorevic et al. | Overview of amyloidosis | |
US20210100777A1 (en) | Heat shock protein (hsp) inhibition and monitoring effectiveness thereof | |
AU2020396471A1 (en) | Peptide-based synthetic chloride ion transporters | |
US10512636B2 (en) | 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161226 |